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Abstract 
The pharmaceutical industry has long been recognised by criminologists as causing social 
harms towards individuals and groups, by engaging in unethical and illegal business 
practices in the pathological pursuit of profit (Braithwaite, 1984; Bakan, 2004). This article 
argues that the neoliberal state is complicit and contributes to pharmaceutical harms due 
to its reluctance to effectively prohibit and sanction these (Tombs and Whyte, 2015). 
Neoliberal national healthcare politics and policies have also created rationale and 
opportunities for private profit creation by the pharmaceutical industry, and resultant 
social harms (Harvey, 2005; Dorling, 2014). Using a zemiological approach, this article 
specifically examines why women as healthcare recipients are disproportionately affected 
by pharmaceutical harms (Szockyi and Fox, 1996). It argues that women who experience 
social harms caused by the pharmaceutical industry are perceived primarily in relation to 
their reproductive and sexualised bodies, resulting in devaluation of their health and 
obscuring of state-corporate harms caused.  
 
Introduction     
The pharmaceutical industry is a known perpetrator of mass social harms on a global 
scale, which alongside their corporate profits are on the rise (Braithwaite, 1984/2014; 
Clinard and Yeager, 2006; Goldacre, 2013; Dukes et al., 2014). Pharmaceutical harms are 
also enabled by neoliberal states through problematic legislative frameworks which 
regulate rather than prohibit harms, prioritising corporate financial health rather than 
that of its citizens (Harvey, 2005; Dorling, 2014; Tombs and Whyte, 2015). 
Pharmaceutical harms are also justified by corporations and states through public 
discourses which deploy utilitarian arguments that any ‘collateral’ harms caused are in 
‘the common good’ to enable medical or societal advances (Lee and Kohler, 2010; 
Rawlinson and Yadavendu, 2015). Everyone does not experience these harms equally 
however, as individuals and groups are affected differently by these dependent upon 
their societal position (Slapper and Tombs, 1999; Croall, 2008). Women as a specific 
group are argued to be disproportionately affected by pharmaceutical harms due to their 
(presumed) reproductive abilities (Claybrook, 1996; Finley, 1996). This assumption as 
Barton notes, is closely tied to: ‘The image of the ‘normal’ woman…based around an 
idealised concept of femininity, which in turn is constructed around dominant discourses 
of domesticity, motherhood, sexuality and pathology’ (1996:1). Deviation from these 
idealised norms of femininity which define acceptable and unacceptable female 
behaviour have been used throughout history to regulate women through the 
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deployment of diverse control strategies including the criminal justice system, to dismiss 
their experiences of harms caused to them (Barton, 1996:1). These dominant discourses 
about women can be seen in relation to women’s experiences of pharmaceutical harms, 
enabled by a complicit state. 
This article analyses how women as healthcare recipients are disproportionately 
affected by harms perpetrated by the pharmaceutical industry aided by a complicit 
neoliberal state, utilising a Foucauldian feminist and zemiological analysis. This approach 
is useful in explaining how women are governed across multiple social sites in relation to 
their health. Relationships between women, the pharmaceutical industry and the state 
for example, are shaped by wider social processes where social controls are exercised 
upon women, such as norms and ideals of ‘appropriate femininity’ which they are 
expected to conform to (Foucault, 1980; Sawicki, 1991; Madriz, 1997; Hillyard and 
Tombs, 2004). Using examples from this under-researched area, this article argues that 
women’s (presumed) reproductive abilities make them particularly vulnerable to 
pharmaceutical harms (Claybrook, 1996; Finley, 1996; Nippert et al., 2002; Tombs, 
2016). It presents a detailed case study of the vaginal mesh ‘scandal’ due to the lack of 
zemiological and criminological, rather than medicalised debates surrounding this.2  
A documentary analysis of sources including public health documents, news 
media articles, books and journal articles have been utilised in this research (Mason, 
1996:71-9). Sources were found via an extensive on-line literature search involving key 
words such as ‘pharmaceutical harm’, ‘women’, ‘vaginal mesh’ and ‘breast implants’. Due 
to the dearth of zemiological and criminological knowledge around pharmaceutical 
harms to women particularly those involving vaginal mesh, the research aimed to gather 
existing academic, public, medical and state-corporate knowledge in this area (cf. Peppin, 
1995; Claybrook, 1996; Finley, 1996; Croall, 2008). It also aimed to challenge 
‘conventional’ scientific rather than zemiological or criminological discourses about 
pharmaceutical harms to women (Foucault, 1980:81-2; Mason, 1996:3). The research 
examined how effective state-corporate processes ostensibly designed to prevent 
pharmaceutical harms to women were, and how women’s experiences of these harms 
were discussed. Where quotes from, or information about women harmed by 
pharmaceutical products are used, these are from publicly available sources rather than 
primary research, thus minimising potential ethical issues (Mason, 1996:78).  
The article makes two main points in relation to gendered pharmaceutical harms. 
Firstly, it argues that largely preventable and foreseeable gendered pharmaceutical 
harms perpetrated by pharmaceutical companies and an enabling state, are justified 
through a utilitarian calculus which prioritises medical and social advancements above 
‘collateral’ harms to women. Secondly, it argues that government neoliberal discourses 
in relation to health are worsening the obfuscation of gendered pharmaceutical harms 
and state-corporate accountability for these. It then concludes after a discussion of the 
possibilities for resistance to pharmaceutical harms to women. The aim of this article is 
not to repeat notable existing discussions in relation to the harmful corporation per se 
(Braithwaite, 1984/2014; Dukes et al., 2014; Tombs and Whyte, 2015; Tombs, 2016). 
Rather, it aims to bring a detailed examination of gendered pharmaceutical harms (again) 
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to the forefront of critical criminology’s attention (Mintz, 1985; Claybrook, 1996; Finley, 
1996; Croall, 2008). 
 
 
Pharmaceutical Harms under Neoliberalism  
The pharmaceutical industry has long been recognised as a perpetrator of mass social 
harms in a range of diverse ways by criminology (Braithwaite, 1984/2014). 
Criminologists including corporate and white-collar crime scholars have given 
comparatively little attention however, to pharmaceutical harms in comparison to other 
forms of social harm (cf. Braithwaite, 1984; Croall, 2008; Dukes et al., 2014; Rawlinson 
and Yadavendu, 2015; Tombs and Whyte, 2015; Rawlinson, 2017). A notable exception 
to this is Braithwaite’s seminal study (1984/2014) into corporate crime within the 
pharmaceutical industry, which found extensive and global wrong-doing within 
companies resulting in social harms towards consumers. He found that pharmaceutical 
companies engaged in illegal, unethical and harmful behaviours such as bribing 
government officials, use of dangerous manufacturing processes, negligence and fraud in 
drug safety testing. Despite this evidence, there is still a widespread public expectation 
that the pharmaceutical industry will research, develop and produce drugs for ‘the 
common good’ so as to improve rather than harm public health outcomes. Using this 
utilitarian justification, it is also presumed that ‘collateral’ harm is inevitable to enable 
medical and social advances (Lee and Kohler, 2010). This rationale however is 
problematic as has been used throughout history, to justify mass harms and atrocities 
such as the Holocaust by Hitler’s Nazi Germany during World War Two, Thalidomide and 
pharmaceutical trials on those living in the Global South to benefit the health of 
individuals in Western countries (Rawlinson and Yadavendu, 2015).3  
The presence of a ‘state-pharma nexus’ (Rawlinson, 2017) whereby states enable 
the harm causing behaviours of the pharmaceutical industry is also clear. The 
pharmaceutical industry is known for example, to breach laws ostensibly meant to 
prevent social harms (Braithwaite, 1984/2014; Clinard and Yeager, 2006:xxi). However, 
state legislative frameworks which apply to corporate wrong-doing are often based on a 
misplaced confidence in the criminal law as an impartial adjudicator, rather than a state 
instrument of power reflecting its own capitalist interests which is used to further these. 
Pharmaceutical companies moreover maximise their profits and avoid national 
legislative frameworks by moving their operations to poorer countries with less 
legislative safeguards for workers, consumers and the natural environment, which nation 
states use to attract corporations there (Tombs and Whyte, 2007; 2015; Rawlinson and 
Yadavendu, 2015). State-corporate pharmaceutical harms therefore: ‘often emerge from 
intersections of economic and political power’ and are perpetrated in the pursuit of 
mutual economic and political interests by states and pharmaceutical corporations 
(Michalowski and Kramer, 2006:3). State political decisions therefore can result in 
financial and economic social harm perpetration due to mis-appropriation of public funds 
by governments and private corporations including the pharmaceutical industry via: 
‘…increased prices for goods and services through cartelisation and price-fixing, and 
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redistribution of wealth and income from the poorer to the richer through regressive 
taxation and welfare policies’ (Hillyard and Tombs, 2004:19).  
 
Neoliberalism, Health and Harms 
Neoliberalism continues to exert a considerable influence upon state political policies, 
which has created almost perfect conditions for pharmaceutical profit maximisation and 
increased harm perpetration. As a political ideology, neoliberalism encourages the 
private owners of capital and production to create profit through a hegemonic project 
which concentrates power and wealth within elite groups to the detriment of other social 
groups (Saad-Filho and Johnston, 2004:1). In relation to health, the neoliberal agenda 
continues to worsen and legitimate rising inequalities and to cause social harms, through 
beliefs in macroeconomic policies and market reliance to solve wider structural 
inequalities (Harvey, 2005; Stuckler and Basu, 2013; Dorling, 2014). Individuals and 
groups who already find themselves marginalised within society because of class, ‘race’, 
age, gender, sexuality and (dis)ability, are disproportionately affected and harmed by 
neoliberal policies which prioritise corporate fiscal health over citizens’ health (Connell, 
2014; Bell and Scott, 2016). Neoliberalism’s impact upon women includes worsening the 
impact of existing structures in society which position them in a subordinate socio-
economic position in relation to men; structures which are essential to the accumulation 
of capital (Braedley and Luxton, 2014).   
In the United Kingdom (UK), the public healthcare budget for the National Health 
Service (NHS) was ostensibly protected from austerity measures but had significant 
spending cuts due to a lack of inflationary increases which were obscured from public 
debate at the time (HM Treasury, 2010). These have resulted in patient fatalities and 
harms in UK hospitals and in the wider community (Francis, 2013; Dorling, 2014). A 
mistaken neoliberal assumption that markets, competition and profits will always be 
preferable to state interventions however, has encouraged government policies and 
subsidies enabling the growth of private and corporate profit seeking parts of the 
healthcare sector where: ‘…private profiteers are replacing dedicated doctors.’ (Stuckler 
and Basu, 2013:106). This has directly led to the demise of public healthcare provision 
which has become a: ‘…residual system, the second-best choice for those who can’t afford 
the real thing.’ (Connell, 2014). Government neoliberal agendas also emphasise 
individual responsibility for, rather than a right to health, to blame individuals for their 
poor health and to justify reduced public spending on healthcare whilst private corporate 
profits benefit from the provision of services and goods which ‘fill the gap’ (Hillyard and 
Tombs, 2004; Polzer and Power, 2016).  
A neoliberal political economy of health which concerns political power over 
resource allocation, has also helped the pharmaceutical industry to exert a ‘…deeply 
concerning’ power and political influence over healthcare, through doctors and 
governments (Mooney, 2012:7). The UK House of Commons Health Committee states: 
‘The industry is hugely influential, affecting every aspect of the medical world, including 
prescribers, patients, academics, the media, and even the institutions designed to 
regulate it. Its influence in Parliament is extensive’ (2005:8). The pharmaceutical 
industry therefore, is unlikely to be held accountable for harm perpetration by a complicit 
state. The pharmaceutical industry has also encouraged ‘pharmamedicalisation’; an 
unhealthy reliance and over-use of drugs in health conceptualisation and administration 
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(Rawlinson, 2017:95). This leads to a perception that pharmaceutical products are 
essential for the health and wellbeing of individuals and groups within society, whilst 
exposing them to increased risks of drug-related illnesses and financial harms through 
mis-use of personal and public funds. Aided by a neoliberal emphasis on privatisation and 
a free economic market, pharmaceutical companies also take advantage of their 
privileged position in healthcare to engage in profiteering through charging the NHS 
excessive drug prices due to weak public-sector bargaining mechanisms (Hillyard and 
Tombs, 2004; House of Commons Health Committee, 2005:8). The pharmaceutical 
industry also receives public subsidies to encourage innovative drug development for 
private profit, which is more expensive and less profitable than developing similar ‘me-
too’ drugs based on existing drugs (Goldacre, 2013).  
The state is also responsible for enabling social harms caused by the 
pharmaceutical industry through its regulation rather than prohibition of pharmaceutical 
harms, further encouraged by a neoliberal agenda of deregulation which prioritises 
private profit over public health and safety (Tombs and Whyte, 2007; 2015). Within the 
UK, regulators such as The National Institute for Health and Care Excellence (NICE) and 
the Medicines and Healthcare Products Regulatory Agency (MHRA) increasingly perceive 
pharmaceutical companies as their customers rather than patients leading to the 
establishment of: ‘...a ‘neo-liberal corporatist partnership’  with the industry (Davis and 
Abraham, 2012:493).4 This results in the pharmaceutical industry dictating strict targets 
for the speed of drug review and marketing approval in exchange for extensive secrecy 
over regulatory decision-making and industry fees, raising concerns about patient safety 
and drug efficacy. The pharmaceutical industry has also succeeded in shortening costly 
drug trials resulting in ‘surrogate outcomes’, which may give misleading results about 
drug efficacy and effectiveness for longer term patient use. Pharmaceutical companies 
also often engage in ‘ghost-writing’ of academic and non-academic journal articles known 
to influence public policy and public opinion, which they sponsor to present more 
positive outcomes for the industry (Mooney, 2012; Goldacre, 2013).  
 
Gendered Pharmaceutical Harms to Women 
A dearth of criminological attention has been paid to pharmaceutical harms specifically 
in relation to women (see for exceptions Peppin, 1995; Claybrook, 1996; Finley, 1996; 
Croall, 2008). This is arguably due to a general ‘gender blindness’ within criminology in 
relation to all forms of corporate crime (Croall, 2008:137). Generally, the chances of 
women experiencing certain types of corporate social harm can be affected by the work 
they do, job-related restrictions due to exclusions applying to women based on 
reproductive or other sex-based hazards or discrimination, the separation of home work 
from paid labour, and societal cultural norms and standards in relation to masculinity 
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and femininity (Simpson and Elis, 1996:33-34). This is different from arguing that women 
experience corporate social harms more than men as a societal group. Rather, women are 
more vulnerable to experiencing certain types of pharmaceutical harms due to societal 
and cultural factors including (men’s) desire to change or alter women’s bodies (Croall, 
2008:137). Women are specifically vulnerable to the risk of ‘gender-specific’ or gendered 
pharmaceutical harms because of social and cultural norms about their (presumed) 
reproductive abilities in relation to childbirth, pregnancy, ovulation and menstruation, 
which men cannot directly experience. Throughout history, women’s bodies have been 
medicalised, subjected to intrusive forms of surveillance and thus social control, and 
perceived as more liable to ill health than the male body. They have also been perceived 
as a site of contamination due to associations with fluids and leakage tied to their 
assumed reproductive capacities (Barton, 1996; Bridgeman and Millns, 1998). 
Consequently, women are more likely to experience the medical profession than men, to 
undergo more potentially harmful medical and surgical interventions, and are therefore 
more vulnerable to pharmaceutical harms (Petersen and Lupton, 1996; Schlichthorst et 
al., 2016:1028).  
In relation to pharmaceutical harms to women, Foucault’s concept of biopower 
allows a critical examination of how gendered medicalised discourses are inextricably 
linked to state power. Conceptually, biopower captures all the forms which power takes 
towards individuals within society which subject them to sexual and biological norms. 
Biopower relates to the administration of life itself and includes two connected forms. 
The first of these Foucault termed ‘an anatomo-politics of the human body’ and 
concentrates on the disciplining of the individual body as a machine (1990:139). It is 
focused on optimising the body’s usefulness and its docility, and its incorporation into 
efficient economic systems through processes of power. Part of this process are medical 
norms which define individuals in relation to their health and categorise it as ‘unhealthy’ 
‘ill’ or ‘abnormal’. Arguably added to these is ‘incomplete’, in recognition of the gendered 
and sexualised discourses which surround the neoliberal female body of health. Once an 
individual’s body is categorised; a process which invariably relates to social exclusion or 
marginalisation, a health industry exists to both continually service and remedy this 
‘inadequacy’ or ‘lack’, such as the diet, cosmetic surgery, or the ‘mothering’ industry. The 
politics and economics of corporations including those of the pharmaceutical industry 
are closely connected to these. Due to the influence of neoliberalist politics and economics 
upon the state which emphasises the primacy of corporate profit making in a free market, 
pharmaceutical companies are then optimally placed within this not just to create mass 
profits, but also mass social harms (Harvey, 2005). Neoliberalist influences upon the state 
means that historically established forms of corporate regulation and criminal sanctions, 
however flawed, become less effective through a loosening of ‘corporate red tape’ to 
enable profit making (Tombs and Whyte, 2015).  
The second form of biopower Foucault termed ‘…a bio-politics of the population’, 
focused on social groups in relation to the human body, its ability for reproduction and 
the ‘mechanics of life’ such as births, mortality, health levels, life expectancy and longevity 
(1990:139). Significantly, Foucault was concerned with examining all the conditions that 
cause these to vary. This form of biopower of the population is concerned with states or 
governments harnessing human bodies, both as a resource to be used and protected, 
which are subjected to forms of surveillance aiming to improve them. Public health 
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campaigns about sexual health, breast feeding, exercise or healthy eating, and dictatorial 
and/or punitive societal discourses around those who do not meet these norms, are all 
forms of this type of biopower. Foucault examined how these forms of regulatory control 
were affected on and through individuals in society. Significantly, biopower has been an 
essential element in the development of capitalism and thus the dominance of the 
corporation as it: ‘…would not have been possible without the controlled insertion of 
bodies into the machinery of production to economic processes.’ (Foucault, 1990:141). It 
also needed these bodies to be docile and to have methods of power to make them so. 
Following this, a bio-politics of the population as a form of biopower, must have also been 
‘…indispensable to patriarchal power as it provided instruments for the insertion of 
women’s bodies into the machinery of reproduction.’ (Sawicki, 1991:68). Patriarchy 
defined in Foucauldian terms is: ‘…a global effect of domination made possible by a 
myriad of power relations at the microlevel of society.’ which acknowledges that there is 
no general theory which can encapsulate this, nor one location or place of resistance 
(Sawicki, 1991:59). It recognises that certain groups of men, for example, those who are 
gay or working-class, can also be subject to patriarchy. Feminist struggles for women’s 
control of their own bodies have been part of the history of biopower (Sawicki, 1991:68) 
Neoliberalism which is dependent upon capitalism and patriarchy, influences how 
women who experience pharmaceutical harms are perceived and their agency relating to 
their health. The aforementioned ‘responsibilised individual’ which neoliberalism 
advocates, is based upon a comparatively socially and economically advantaged male 
subject encouraged to rely on their own resources to solve health issues and to make ‘free 
choices’, often through the neoliberal co-option of feminist discourses of empowerment. 
Although under neoliberalism women may feel empowered and able to exercise ‘choice’ 
in relation to healthcare, they must make the ‘right’ choices as consumers of products 
rather than recipients of care (Scharff, 2016). The neoliberal rhetoric of ‘choice’ is also 
problematic as it ignores health inequalities, cultural and social idealised norms of 
femininity which continue to devalue, oppress and subordinate women because of their 
(presumed) reproductive abilities. Women’s citizenship is also dependent upon their 
responsibility not to become ill due to their negligence nor to become a burden on their 
family or the state, through engaging in state and self-surveillance and bodily regulation 
activities (Petersen and Lupton, 1996:79-80; Bell and Scott, 2016). Neoliberal emphasis 
upon women’s individual responsibility for their health means that when they experience 
pharmaceutical harms in relation to their (presumed) reproductive abilities, these are 
justified through a neoliberal lens which emphasises a teleological, linear and egalitarian 
account of medical and social development, thereby undoing the need for social 
movements such as feminism to effect change. These gendered harms are then obscured, 
dismissed and trivialised, with women blamed for these (Claybrook, 1996; Finley, 1996; 
Foucault, 2002; Polzer and Power, 2016; Scharff, 2016).  
A further impact of this is that when women have tried to legally pursue 
companies to gain compensation for pharmaceutical harms caused to them, their 
reproductive injuries have not been placed at a high value due to societal and cultural 
norms which devalue women’s bodies (Finley, 1996). Reproductive harms are also 
devalued as they are not easy to quantify, are perceived in emotional rather than physical 
or economic terms, and are minimized as too subjective. This is closely tied to the 
construction of women as ‘emotional’ and ‘hysterical’; terms used throughout history to 
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dismiss their experiences and complaints about harms caused to them (Worrall, 1990; 
Barton, 1996:11). Therefore, although used as a societal means to control women: ‘While 
supposedly a priceless asset in cultural terms, economically speaking, a woman’s 
reproductive capacity is virtually worthless.’ (Finley, 1996:75). Gendered pharmaceutical 
harms to women based upon their (presumed) reproductive abilities are not therefore a 
rare ‘aberration’, rather they are a common occurrence and risk in women’s lives, as 
shown by the following examples.  
 
A Brief History of Gendered Pharma-Harms 
In the 1930’s, diethylstilbestrol or DES was a synthetic estrogen used to treat pregnant 
women for morning sickness and to ensure that their babies were born healthy. Despite 
tests on animals which proved the potential harms of using the drug, it continued to be 
marketed and sold and its use resulted in women suffering miscarriages, infertility and 
babies being born ‘deformed’. The FDA did not allow pharmaceutical companies to use 
DES for unapproved uses such as in pregnant women. Pharmaceutical representatives 
however, encouraged doctors to use the drug on pregnant women and donated supplies 
of the drug to enable this. Finley argues: 
The exclusive focus of the pharmaceutical industry on what DES might do 
for women, instead of also on what it might do to women, demonstrates 
their greater concern for controlling the female reproductive system for 
profit than for the ultimate health and safety of women. (Finley, 1996:63-
64) 
Women also experienced ‘victim-blaming’ based on idealised norms of femininity when 
they brought legal cases against pharmaceutical companies for harms it had caused them. 
Women were accused of causing these harms through their lifestyle and sexual behaviour 
such as having more than one sexual partner, and/or a sexually transmitted disease 
which had caused their infertility (Barton, 1996:1). In the 1960’s, the Dalkon Corporation 
and then later A.H. Robins manufactured the Dalkon Shield; an intra-uterine 
contraceptive device. It was marketed and sold despite corporate knowledge of issues 
with the material used for the device’s filament strings, which were dangerous to women 
as infection could be carried directly into the womb through the wicking of the strings. 
Thousands of women who had a Dalkon Shield device inserted suffered miscarriages, 
infertility, infections and unwanted pregnancies. Pharmaceutical companies again tried 
to evade responsibility through bankruptcy and engaged in ‘victim-blaming’ utilising 
idealised norms of femininity to interrogate women with degrading questions about their 
previous sexual partners, lifestyle and ‘toilet habits’ (Mintz, 1985; Finley, 1996:87).  
The thalidomide ‘scandal’ erupted in 1962 in America and involved a sedative 
drug prescribed to women for morning sickness which caused babies to be grossly 
deformed. Pharmaceutical manufacturers ignored known dangers of the drug and 
publicly denied any link to harm. The ‘scandal’ resulted in a legal change which meant 
that a drug’s effectiveness needed to be proved before it could be approved for sale by 
the Federal Drug Administration (FDA); the United States of America’s (USA) drug 
regulatory body. Thalidomide continues to cause harms in the lives of those women and 
their children (Nippert et al., 2002). Moreover in 2010, 400,000 female patients in 55 
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different countries were affected by Poly Implant Prothese (PIP) breast implants 
manufactured by French company Poly Implants Prosthese Prothese (Oulharj et al., 
2014:304). PIP breast implants were withdrawn from UK markets after it was discovered 
that the implants had been fraudulently manufactured using cheap industrial rather than 
medical grade silicone which had saved the company 1.2 million euros. Jean-Claude Mas; 
the company’s founder, fraudulently misled the French authorities about the implants’ 
safety and efficacy through ignoring safety tests, whilst exposing women to ill health. A 
French criminal court case convicted him of aggravated fraud and sentenced him to four 
years imprisonment with a €75,000 fine (£63,000) involving 7,113 women from 71 
countries as plaintiffs. Four company executives were also imprisoned (Benkimoun, 
2013).  
In common with other gendered pharmaceutical harms, the PIP ‘scandal’ had 
striking similarities to 1991 when the Dow Corning Corporation in America was found 
liable for fraud, malice and oppression in the manufacture and sale of defective and 
unsafe silicone gel breast implants. The claimant Mariann Hopkins was awarded damages 
for suffering from an immune disorder after she was exposed to silicone gel from breast 
implants which were inserted after a double mastectomy. The court found that Dow 
Corning had acted knowingly with disregard for her safety and rights, exposing her to 
cruel and unjust hardship. Far from being an isolated incident, earlier in 1984 Dow 
Corning had been found similarly liable for ‘corporate malice’ in a product liability 
lawsuit for silicone breast implants against Maria Stern. The case was the first of its kind 
to be tried successfully and Stern was awarded $1.5 million in punitive damages. Dow 
Corning knew in 1972; twenty-one years before Mariann Hopkins brought her case to 
trial that silicone could move to other parts of the body including the immune system. 
Many more women harmed by all these cases of pharmaceutical harms never and 
understandably, undertook the arduous route of legal action (Claybrook, 1996).  
The gendered pharmaceutical harms caused to women by drugs given during 
pregnancy, contraceptive devices, and faulty breast implants are however not isolated 
incidents. They are as the following discussion about vaginal mesh implants will show, 
characteristic of corporate pharmaceutical deviance throughout history repeating itself, 
and women’s bodies continuing to be harmed due to cultural factors and attitudes which 
focus more on the benefits of medical ‘progress’ which have benefitted pharmaceutical 
companies enabled by a complicit state, rather than the overwhelming dangers of 
pharmaceuticals to women’s health. Although women generally have gained reproductive 
‘freedom’ and ‘choice’ through medical advances in contraception, this has not been 
without significant harms caused to women as a social group. It has also produced 
significant benefits for men as a social group in relation to reproductive responsibility, 
which women are still largely responsible for. As the following discussion of the vaginal 
mesh ‘scandal’ will show, these harms continue in the present day (Finley, 1996:92). The 
persistence of these gendered harms may also show an acceleration of pharmaceutical 
corporate harms due to the inability of pharmaceutical companies, and corporations 
generally, to not cause harm to women through engaging in unethical and illegal business 
practices in the pathological pursuit of profit (Braithwaite, 1984/2014; Bakan, 2005; 
Dukes et al., 2014; Tombs and Whyte, 2015).  
 
The vaginal mesh implant ‘scandal’ 
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In the UK in 2017, NICE issued clinical guidance on the use of mesh in transvaginal repair 
of anterior or posterior vaginal wall prolapse in women due to childbirth or to treat 
urinary incontinence. NICE recommended that transvaginal mesh repair should only be 
used in the context of research, as there was evidence of serious and well-recognised 
safety concerns about their use and inadequate evidence about their long-term 
effectiveness (2017:2). Based on existing clinical studies NICE estimated that twelve per 
cent of women who had vaginal mesh experienced complications after two years of 
implantation, with nine per cent needing removal of it. They noted that when 
complications occurred in women that ‘…these can be serious and have life changing 
consequences.’ (2017:8). In comparison, only one per cent of women who had a biological 
graft made from their own or sterilised cadaveric tissues implanted experienced 
complications (NICE, 2017:5; Campbell, 2018). Transvaginal repair with mesh involves 
removing some tissue which has been stretched and tightening the underlying tissue. 
Mesh is used to support the repair and the operation is usually done under general 
anaesthetic (NICE, 2017:3). The mesh is usually made from polypropylene plastic as it 
can withstand an autoclave and be used in the manufacture of medical devices (Campbell, 
2018). Mesh devices differ in pore size and fibre configuration, can include a non-
absorbable coat covered with a thin layer of collagen and their size can vary. Around 
10,000 women a year in the UK have vaginal mesh implanted, and from 2006 to 2017, 
over 130,000 women were implanted with vaginal mesh, and 6,000 women underwent 
procedures to remove or partially remove their mesh implants (Marsden, 2017a; 2017b). 
In America nearly 790,000 vaginal mesh devices were sold, with two million worldwide 
(Dyer, 2016). 
 
The impact on women of vaginal mesh implants 
Serious complications however can occur with vaginal mesh implants as polypropylene 
mesh can shrink by up to half four weeks after implantation (Henegan et al., 2017). 
Women who were fitted with a vaginal mesh repair therefore experienced a range of 
physical harms from infection, urinary retention, dyspareunia or other pain, alongside 
other mesh complications (Glazener et al., 2017). Dawn Martin, aged 55 who had vaginal 
mesh implanted to treat incontinence after childbirth experienced chronic pain. She was 
also admitted to intensive care in hospital after having a severe reaction to the painkiller 
used to treat her chronic pain. When she eventually got doctors to agree to remove her 
mesh, reflecting many women’s experiences of state-corporate harms towards them 
being disbelieved or being labelled as ‘hysterical’, they found it had shrunk more than 
expected and was cutting through her urethra into her bladder (Worrall, 1990; Barton, 
1996). She still suffers from health issues saying: ‘I don’t feel attractive anymore. It’s aged 
me by 20 years. I feel like a completely different person’ (quoted in Sanghani, 2017). June 
Smith, aged 67, also experienced chronic pain due to the implant and felt she had broken 
glass inside her. She said: ‘I told my husband I couldn’t continue with the pain and wanted 
to kill myself’ (quoted in Sanghani, 2017). Chrissy Brajcic from Ontario in Canada was 42 
years old when she died of complications after having vaginal mesh fitted. She was left 
bedridden and in pain after her procedure which was to treat minor incontinence. She 
experienced recurrent infections because of the operation and became resistant to the 
antibiotics used to treat her. She then later contracted sepsis and died of organ failure 
(Marsden, 2017b). 
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A common issue of the women who received vaginal mesh implants and similar to 
other pharmaceutical harms, was the absence of their informed consent due to their lack 
of knowledge about the risks and benefits of the treatment. Ethicon, the Johnson and 
Johnson division which marketed vaginal mesh, did not inform women nor doctors that 
it had mainly been tested upon sheep and in a short-term medical trial lasting a few days 
on only thirty-one women (Marsden, 2017b).5 The trial was unlikely to reflect the long 
term harmful impact to women of implanting vaginal mesh in them as due to biological 
incompatibility, non-human trials are not comparable to those on humans. Human 
medical trials are therefore essential to assess the potential long-term impact and harms 
of any medical device but as argued earlier, these are often costly and avoided by 
pharmaceutical companies or are often shortened with ‘surrogate end points’, which 
mean that the harmful long-term effects of drugs are masked until consumers use them 
(Goldacre, 2013; Henegan et al., 2017). It has also been alleged that Ethicon did not fully 
inform doctors of the risks of using vaginal mesh in women and hid its knowledge about 
potential adverse effects including those which were permanent. This resulted in 
lawsuits against Johnson and Johnson in multiple jurisdictions (Dyer, 2016; Richards, 
2017). 
 
The failure of regulatory frameworks 
Significantly, the governance of medical devices by state regulatory bodies which 
approved the marketing of synthetic vaginal mesh products in the USA and Europe was 
problematic (Henegan et al., 2017). This reflects wider concerns raised by criminologists 
in relation to the (in)effectiveness and (in)ability of state regulatory structures to hold 
corporations accountable for their harmful actions (Braithwaite, 1984/2014; Dukes et 
al., 2014; Tombs and Whyte, 2015). In common with other pharmaceutical harms 
‘scandals’ involving women previously discussed, the potential harms of vaginal mesh 
implants were known about or alternatively ignored for decades by their manufacturers 
before they were marketed, as they were not tested on a meaningful sample of women 
during trials (Marsden, 2017b). Significantly, the mass pharmaceutical harms caused to 
women by vaginal mesh implants had also been known in the medical world for some 
time before the ‘scandal’ erupted in 2017. In the UK for example, NICE knew in 2005 that 
there was a need for vaginal mesh studies with longer term follow up, and said that 
women should be informed about the lack of any long-term data about health outcomes 
(Henegan et al., 2017).  
In the European Union (EU), manufacturers of medical devices need to apply to 
any ‘notified body’ in an EU country to gain approval for its marketing across any country 
within the EU. Within the UK for example, the MHRA authorise ‘notifiable bodies’ which 
assess whether manufacturers and their medical devices meet safety and efficacy 
requirements set out in relevant EU legislation in relation to a product (UK Government, 
2017). Once approved under this process, manufacturers are issued with a certificate and 
allowed to use the CE ‘quality’ mark which signifies that it meets EU health, safety and 
                                                          
5 In Schloendorff v Society of New York Hospital 105 NE 92 (NY, 1914) Cardozo J defined informed 
consent as: ‘Every human being of adult years and sound mind has a right to determine what shall 
be done with his own body; and a surgeon who performs an operation without the patient’s consent 
commits an assault.’ (Laurie et al., 2016:68). 
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environmental standards (UK Government, 2012). NICE work closely with the MHRA to 
ensure that information about a medicine or treatment’s safety and efficacy is shared 
appropriately to enable effective decision-making about it (Department of Health and 
Medicines and Healthcare Products Regulatory Agency, 2016). This regulatory process 
ostensibly meant to ensure the safety and efficacy of a medicine or treatment however, 
failed in relation to the approval of vaginal mesh implants. This is perhaps unsurprising 
as regulatory systems have been criticised for being inadequate in ensuring patient 
safety, as their decision to approve a drug or medical treatment is based upon insufficient 
evidence about its safety and efficacy. Instead it relies on its ‘presumed’ similarity to a 
previously approved product, which could have gained approval over a decade before 
(Henegan et al., 2017:5-7).  
Despite strong objections by the industry themselves, pharmaceutical products 
and devices are legally regulated under the Consumer Protection Act 1987.6 This creates 
strict liability so that consumers only need to prove a causal act without any form of mens 
rea such as intent, negligence or recklessness, by a company. A degree of safety which 
‘persons generally are entitled to expect’ is applied to pharmaceutical products under 
section 3(1). Manufacturers however will not be liable for defects which they could not 
be expected to discover at the relevant time of manufacture due to the state of scientific 
and technical knowledge at the time under section 4(1)(e). This is problematic as for 
example, the investigating authority for the MHRA in the PIP breast implant ‘scandal’ 
discussed previously, concluded that lack of clinical data and poor record keeping by 
manufacturers resulted in inconclusive evidence as to the health and safety of the 
implants. The UK Department of Health’s Report into PIP breast implants also agreed 
with this conclusion (Laurie et al., 2016:170-171). This in effect rewards corporations 
who intentionally, negligently or recklessly decide not to keep effective record to 
maximise profit margins and can be used to evade legal claims made against them. 
In America, pharmaceutical products are regulated by the Federal Drug 
Administration (FDA), whose effectiveness as an independent regulatory and 
enforcement agency which ensures the safety and effectiveness of pharmaceutical 
products is questionable, as it receives it’s funding from pharmaceutical companies 
themselves (Dukes et al., 2014:170). Significantly in relation to vaginal mesh, the FDA 
first approved synthetic polypropylene mesh for use in hernia repair between 1985 and 
1995, but significantly no vaginal mesh was approved. In 1996, Boston Scientific’s 
ProteGen® mesh was the first approved specifically for use in vaginal prolapse 
procedures. Controversially however, it was approved under the FDA’s 510(k) pre-
marketing notification process which allows manufacturers to market a new product 
without considerable testing if it is thought to be substantially equivalent and at least as 
safe and effective as a legally marketed device, as it was based on pre-approved mesh for 
hernia repair. No further testing was therefore needed despite an absence of safety tests 
on the surgical use of mesh in women for vaginal prolapse (Campbell, 2018:51-52). FDA 
approval was given for a vaginal mesh product which was significantly different from the 
one initially approved due to a series of approvals which resulted in ‘predicate creep’: 
‘…whereby the numerous changes result in a new device that is very different from the 
original predicate device.’ (Henegan et al., 2017:1). State regulatory structures in both the 
                                                          
6 European Union Council Directive 85/374/EEC on product liability. 
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UK and America specifically therefore did not prevent pharmaceutical harms to women 
which were known to both manufacturers and regulators, due to a neoliberal agenda 
which prioritises the profits of corporations in the mutual interests of the state 
(Michalowski and Kramer, 2006:3). The UK state specifically were also typically reactive 
rather than proactive about the corporate harms of vaginal mesh only after women raised 
social awareness of the issue through collective in addition to individual activism, and 
mass harms had already been caused.  
 
Resisting Gendered Pharma-Harms 
Resistance against pharmaceutical companies in relation to gendered harms is crucial in 
trying to tackle and dismantle harmful corporations and to replace them with less 
harmful alternatives (Tombs, 2016:207-210). Academic arguments can play a key role in 
highlighting state-corporate collusion, resultant harms and in effecting social change. 
More criminological attention is also clearly needed in relation to state-corporate harms 
towards women, including those committed by the pharmaceutical industry. Activism is 
however an essential form of resistance to state-corporate harms which can change the 
course of social events. Throughout history, feminist collective and individual activism 
has secured significant improvements to women’s lives. Specifically, collective activism 
can be an effective ‘antedote’ to individualist and responsibilising neoliberal discourses 
deployed in relation to gendered (pharmaceutical) harms to women which depoliticise 
issues of social harm about women’s health (Scharff, 2016:52-4). Collective activism is 
essential for women to be ‘taken seriously’ and for meaningful social change to occur 
through societal disapproval towards corporate harm perpetrators and complicit states 
(Oakley, 1993:18; Stanley and McCulloch, 2013:4). Activism is also essential to counter 
the prevailing view that the pharmaceutical industry works for ‘the common good’ in the 
interests of patients and their well-being, rather than its own corporate financial well-
being (Goldacre, 2003; Lee and Kohler, 2010).  
In relation to vaginal mesh implants for example, ‘Sling the Mesh’; a UK campaign 
group set up by Kath Sansom for example, advocates on behalf of all women who have 
been affected by them (Sansom, 2018). It has been successful in raising national 
awareness of the harms caused by vaginal mesh implants including gaining the vocal 
support of UK Member of Parliament Owen Smith, which prompted UK government 
action to investigate and then prohibit their marketing (NICE, 2017; Matthews-King, 
2018). Similarly, women harmed by the PIP breast implant ‘scandal’ mentioned 
previously, set up the PIP Action Campaign; a not-for-profit social networking campaign 
across Facebook, Twitter with a central website which is run by those directly affected 
by them (PIP Action Campaign, 2018). Amongst these social networks for example, a 
Facebook group called PIP Implants OPIC (Official PIP Implant Campaign) with over 
1,000 members was set up by women with PIP breast implants. These have raised 
societal awareness of the pharmaceutical harms caused to women and have been a 
crucial site of both support and resistance to their dangers, which were being ignored by 
governments (Roderick, 2017). The collective legal action taken on behalf of women 
harmed by PIP breast implants in France discussed earlier, further demonstrates the 
power of collective action against gendered pharmaceutical harms (Benkimoun, 2013). 
Although they resulted in a successful legal outcome for both women, the litigation 
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against Dow Corning in America of Maria Stern and Mariann Hopkins in relation to harm 
caused by faulty breast implants, shows the difficulties for individual women to challenge 
harms caused by a collectively powerful pharmaceutical industry and complicit state, 
which relied on idealised norms of femininity regarding the individual sexual behaviour 
and lifestyle of women to engage in ‘victim-blaming’ thereby depoliticising gendered 
pharmaceutical harms to them (Finley, 1996:76).  
Significantly, questions about in whose interests do utilitarian justifications in 
neoliberal discourses for medical and social advances such as ‘the common good’ operate, 
need to be raised as this ‘progress’ has often been made at the expense of women’s health. 
To prevent the reoccurrence of the atrocities and harms of the past which were argued 
to be ‘in the common good’ and in the name of ‘progress’, the balance of social harms 
versus benefits to society needs to subjected to careful independent scrutiny, rather than 
leaving this to the likely biased judgement of the pharmaceutical industry, or the 
neoliberal state due to its lack of interest both in preventing rather than regulating 
pharmaceutical harms, and the role of structural constraints (Tombs and Whyte, 2007; 
Rawlinson and Yadavendu, 2015). It is also crucial in undermining neoliberal gendered 
discourses which construct women as individual responsibilised subjects who are 
empowered to make ‘good’ decisions about their health through idealised norms of 
femininity, whilst ignoring the power and influence of a pharmaceutical industry enabled 
by a complicit state, upon women’s experiences as consumers and patients (Barton, 
1996:1). 
Due to the dominance and power of the corporation in society enabled by a 
complicit neoliberal state, discourses of resistance which dispute corporate versions of 
social harm perpetration, are also often hidden, obscured, dismissed or at best somewhat 
listened to and marginalised. Therefore, empowering women so that they are able to 
speak out and ‘strike back’ against the abuses they have experienced is key (Oakley, 
1993:18; Snider, 1996:256; Tombs and Whyte, 2015). Although the harms caused to 
women by vaginal mesh implants were acknowledged eventually for example, the 
neoliberal state and pharmaceutical corporate response to them is still inadequate (NICE, 
2017). Many women with vaginal mesh implants have faced an uphill struggle to be both 
listened to and have these removed, rather than be labelled dismissively by doctors as 
‘hysterics’ (Worrall, 1990; Barton, 1996:1; Sanghani, 2017). It is essential that women’s 
experiences of gendered pharmaceutical harms are recognised as a form of ‘subjugated 
knowledge’. According to Foucault these are: ‘…a whole set of knowledges that have been 
disqualified as inadequate to their task or insufficiently elaborated: naïve knowledges, 
located low down the hierarchy, beneath the required level of cognition or scientificity’ 
(1980:81-82). These are low-ranking or disqualified knowledges from categories of 
individuals in society such as ‘the ill person’ and ‘the psychiatric patient’. Foucault argues 
that criticism and resistance to these forms of power and knowledge is essential and can 
occur and speak truth to power through ‘an insurrection of subjugated knowledges’ 
which uncovers conflicts and struggles which have been obscured. Significantly 
according to Foucault, power and knowledge are not only oppressive but can also be used 
as forms of resistance and become liberatory (1980: 81-82). Subjugated knowledges such 
as the experiences of women harmed by pharmaceuticals including vaginal mesh 
implants, are a key form of resistance as they can undermine neoliberal state-corporate 
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harmful hegemonic discourses and practices, and contribute to a zemiological analysis of 
these.  
 
Conclusion 
This article has argued that despite receiving a limited amount of criminological attention 
due to the gender blindness of corporate crime studies, a critical examination of the 
gendered pharmaceutical harms caused to women by the pharmaceutical industry is vital 
(Croall, 2008). It has shown how the recent vaginal mesh implant ‘scandal’ discussed is 
just one example of a litany of gendered pharmaceutical harms, which continue to be 
everyday experiences in the lives of women globally (Mintz, 1985; Claybrook, 1996; 
Finley, 1996; Nippert et al., 2002). Women’s (presumed) reproductive abilities have 
meant that throughout history, their bodies have been medicalised and subjected to 
surveillance, to control and subjugate them (Bridgeman and Millns, 1998). This has also 
meant that women have been more vulnerable to specific types of corporate harm and 
specifically pharmaceutical harms including in relation to menstruation, pregnancy, 
abortion, miscarriage, and (peri) menopause. Women’s experiences of these harms are 
also dismissed by pharmaceutical corporations aided by a complicit state through the 
mobilisation of idealised norms of femininity which both devalue their (presumed) 
reproductive abilities, and allow the utilisation of individualised and depoliticised 
processes of ‘victim-blaming’ in courts in relation to their sexual behaviour (Barton, 
1996:1; Finley, 1996:93). Pharmaceutical harms caused to women due to their 
reproductive abilities are therefore not a new or novel phenomenon and will 
undoubtedly continue to occur. As Finley argues: ‘For women, a healthy dose of caution 
about reproductive drugs and bodily devices will have to remain the best medicine’ 
(1996:97). 
The neoliberal agenda however gives further opportunities for pharmaceutical 
profiteering and the exacerbation of gendered pharmaceutical harms towards women. 
These will continue to occur with decreasing corporate accountability, due to 
government deregulation measures and infrequent use of the criminal law to punish 
perpetrators. The responsibilising of individuals for their health under neoliberalism also 
gives an easy means for pharmaceutical corporations and complicit states to justify any 
harms caused to them by products that they ‘willingly’ use or consume (Hillyard and 
Tombs, 2004; Polzer and Power, 2010). The author is not arguing for more regulation or 
for more use of the criminal law as both are flawed in holding corporations accountable 
for harm, as they are made by a complicit state in the interests of the powerful which 
includes corporations (Dukes et al., 2014; Tombs and Whyte, 2015). As critical 
criminologists have suggested, it is the very historical roots, design and structure of 
corporations which allow them to evade rather than engage in corporate social 
responsibility; an impossibility when corporate fiscal health must always be placed above 
that of its consumers (Bakan, 2005; Tombs and Whyte, 2015). However imperfect, more 
imaginative solutions need to be used to disrupt the harmful corporation through existing 
mechanisms, such as existing contract law but with an end ‘goal’ of the abolition of the 
corporation (see Tombs and Whyte, 2015; Tombs, 2016:202). In addition to academic 
advocacy, it is the collective activism of women who have been harmed by 
pharmaceuticals in naming their abuse and its perpetrators as has been argued here, 
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where hope of resistance to the neoliberal state-corporate profit machine remains. 
Women’s experiences or ‘subjugated knowledges’ are an essential part of re-writing this 
harmful neoliberal narrative, and in redressing and significantly, preventing these 
injustices (Foucault, 1980). 
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